Peruvian Registry of Clinical Trials (REPEC) published a notification (Press release No. 007-2022-OGITT/INS) on March 15, 2022. This details the measures established for the reception of documents by Documentary Procedure (TD) in a virtual and face-to-face manner.

Submissions and Inquiries via Email:

1. Submission of TD requests, related to all types of new or ongoing clinical trials, not related to COVID-19 can be processed through [email protected].
2. Inquiries and submission of applications for processing of clinical trials related to COVID-19 can be sent through [email protected].
3. Inquiries related to all types of clinical trials, new or in progress, not related to COVID-19 can be sent through [email protected].

General Office of Research and Technology Transfer (OGITT) In-person Attention Table:

In-person assistance will be available through the OGITT Documentary Processing Office, Monday through Friday from 08:00 am to 04:15 pm. Address: National Institute of Health, Jirón Cápac Yupanqui 1400, Jesús María, Peru.

Phone numbers for various types of inquiries are also shared:

1. For inquiries about files: (511) 748 1111 Annex 2155 and 2201
2. For monitoring of Clinical Trials: 51(1) 748-1111, extension 2191 or Cell 975445205
3. For inquiries about REPEC: Tel. 478 1111 annex 2616 Cel. 984108368

For receipt of documents and response by TD:

All requests must be addressed to the General Directorate of the OGITT-INS, and must expressly and specifically indicate the reason for the request. The lifting of the observations issued by the OGITT must be uploaded through the Peruvian Registry of Clinical Trials – REPEC and be notified by email at [email protected], in order to have traceability in monitoring their procedures.

The Peruvian Registry of Clinical Trials (REPEC) published a notification (PRESS RELEASE No. 006-2022-OGITT/INS) on February 03, 2022, stating that-

The services of REPEC Version 2 (V2) have been restored. All the documentation entered through [email protected] during the month of January to date must be regularized in the REPEC V2 in order to have the updated information of the clinical trials presented.

The Peruvian Registry of Clinical Trials (REPEC) published a notification (PRESS RELEASE No. 005-2022-OGITT/INS) on January 26, 2022, stating that-

• From January 06, 2022 (the date since which REPEC Version 2 [V2] is out of service), until the REPEC V2 system is enabled again, all documents must be directed to [email protected] and  [email protected] emails.
• Once the system’s services are restored, this documentation must be regularized in the REPEC V2.

A notification (PRESS RELEASE No. 005-2021-OGITT/INS) dated September 09, 2021, was published on the Peruvian Registry of Clinical Trials (REPEC) website on September 13, 2021. In the context of the same:

Due to preventive maintenance, services of the REPEC Version 2 System will be temporarily suspended as of Sunday, September 12, 2021. The services provided in the previous version of REPEC (REPEC Version 1) will continue as normal.

Note: As of September 24, 2021, the registry website (Version 2) is back to working.

The Peruvian Registry of Clinical Trials (REPEC) published a notification (PRESS RELEASE No. 004-2021-OGITT/INS) on July 23, 2021, as a reminder for the sponsors of clinical trials stating that the authorization of a clinical trial is granted for the total period of time scheduled for its execution. In this context, to request the extension of time for completion of the clinical trial, the sponsor must submit the documents as established in Article 80 of the Clinical Trials Regulations approved by Supreme Decree No. 021-2017-SA within 30 calendar days prior to the end of the validity of the clinical trial.

This is not added as new information, it is a part of the existing regulation.

Measures Established for the Receipt of Documents by Documentary Procedure

Peruvian Registry of Clinical Trials (REPEC) published a notification (PRESS RELEASE No. 003-2021-OGITT/INS) on June 02, 2021. In context of the same:

The General Office of Research and Technology Transfer (OGITT) has enabled the below emails to streamline the procedures regarding the receipt of documentation submitted through the Documentary Processing System of the National Institute of Health (INS).

• Submission of requests for documentary processing related to all types of new or ongoing clinical trials, not related to COVID-19 can be processed through [email protected].
• Consultations and submission of applications for processing clinical trials related to COVID-19 can be done using [email protected].
• [email protected] should be used for consultations related to all types of clinical trials, new or running, not related to COVID-19.

Documents that were sent to the [email protected] mail, as of June 7, 2021, must be sent to the [email protected] mail.

All requests must be addressed to the General Directorate of the OGITT-INS with the specific reason for the request along with a descriptive title. An infographic of the notification is also made available here.

Update on New Version of Peruvian Registry of Clinical Trials (REPEC)

Peruvian Registry of Clinical Trials (REPEC) published a notification (COMMUNICATION N ° 002-2021-OGITT / INS) on January 28, 2021. In context of the new version of the REPEC, developed by the National Institute of Health (INS):

• Any application for new registrations (Sponsor/OIC registration, Research Center registration, Ethics Committee registration, clinical trial authorization), must be made through the newly enabled REPEC Platform.
• The previous REPEC platform will continue to record amendments, reports of adverse events, progress reports, deviations, among others, as well as changes in the conditions of authorization of clinical trials authorized until 2020, with the exception of clinical trials that have as a research product “vaccine candidates” which must use the new REPEC platform.

New Version of Peruvian Registry of Clinical Trials (REPEC)